Literature DB >> 29242304

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Roland B Walter1,2,3, Megan Othus4, Kaysey F Orlowski5, Emily N McDaniel5, Bart L Scott5,6, Pamela S Becker5,2, Mary-Elizabeth M Percival5,2, Paul C Hendrie2, Bruno C Medeiros7, Michael T Chiarella8, Arthur C Louie8, Elihu H Estey5,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29242304      PMCID： PMC5830380          DOI： 10.3324/haematol.2017.182642

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

Authors:  Eric J Feldman; Jeffrey E Lancet; Jonathan E Kolitz; Ellen K Ritchie; Gail J Roboz; Alan F List; Steven L Allen; Ekatherine Asatiani; Lawrence D Mayer; Christine Swenson; Arthur C Louie
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Roland B Walter; Ted A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

3.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

4.  A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

Authors:  G Montalban-Bravo; X Huang; K Naqvi; E Jabbour; G Borthakur; C D DiNardo; N Pemmaraju; J Cortes; S Verstovsek; T Kadia; N Daver; W Wierda; Y Alvarado; M Konopleva; F Ravandi; Z Estrov; N Jain; A Alfonso; M Brandt; T Sneed; H-C Chen; H Yang; C Bueso-Ramos; S Pierce; E Estey; Z Bohannan; H M Kantarjian; G Garcia-Manero
Journal:  Leukemia       Date:  2016-10-31       Impact factor: 11.528

5.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

Authors:  S J Pocock; R Simon
Journal:  Biometrics       Date:  1975-03       Impact factor: 2.571

6.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

Authors:  P F Thall; R M Simon; E H Estey
Journal:  Stat Med       Date:  1995-02-28       Impact factor: 2.373

7.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Authors:  Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

Review 8.  Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.

Authors:  Awa Dicko; Lawrence D Mayer; Paul G Tardi
Journal:  Expert Opin Drug Deliv       Date:  2010-12       Impact factor: 6.648

Review 9.  Management of older or unfit patients with acute myeloid leukemia.

Authors:  R B Walter; E H Estey
Journal:  Leukemia       Date:  2014-07-09       Impact factor: 11.528

10.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Authors:  Daisuke Araki; Brent L Wood; Megan Othus; Jerald P Radich; Anna B Halpern; Yi Zhou; Marco Mielcarek; Elihu H Estey; Frederick R Appelbaum; Roland B Walter
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544
View more
  3 in total

1.  A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Authors:  Sarah A Buckley; Mary-Elizabeth Percival; Megan Othus; Anna B Halpern; Emily M Huebner; Pamela S Becker; Carole Shaw; Mazyar Shadman; Roland B Walter; Elihu H Estey
Journal:  Leuk Lymphoma       Date:  2018-10-02

Review 2.  Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.

Authors:  Jorge E Cortes; Priyanka Mehta
Journal:  Am J Hematol       Date:  2021-01-12       Impact factor: 10.047

3.  Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Authors:  Lucas C Zarling; Megan Othus; Brenda M Sandmaier; Filippo Milano; Gary Schoch; Chris Davis; Marie Bleakley; H Joachim Deeg; Frederick R Appelbaum; Rainer Storb; Roland B Walter
Journal:  Leukemia       Date:  2022-04-19       Impact factor: 12.883
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.